Semaglutide for the Treatment of Obesity in Children 6 to <12 Years of Age
Source: View publication →
In a phase 3 trial involving children aged 6 to under 12 years with obesity, once-weekly subcutaneous semaglutide treatment yielded a 13.5% mean reduction in BMI at 68 weeks, significantly greater than the 2.7% increase seen with placebo.
Key Findings
Study Design
Study Limitations
Clinical Significance
This trial robustly demonstrates the efficacy and tolerability of once-weekly semaglutide in pre-adolescent children (6 to <12 years) with obesity. Given the paucity of durable, efficacious pharmacologic interventions for this highly vulnerable demographic, these findings support GLP-1 receptor agonism as a powerful tool to reverse severe childhood obesity trajectories before adulthood.
Historical Context
Childhood obesity is a chronic neurometabolic disease with limited treatment options. Prior to the STEP Young trial, once-weekly semaglutide had established a new standard of care for adolescents (STEP TEENS) and adults (STEP 1-5 trials), achieving remarkable weight reductions. However, younger children (under 12 years) only had older, less effective, or daily-injection options such as liraglutide (SCALE Kids trial). This 2026 study addressed the critical gap by validating the use of the highly effective semaglutide 2.4 mg platform in a younger pediatric cohort.
Guided Discussion
High-yield insights from every perspective
What is the primary mechanism of action of semaglutide, and how does targeting this specific endocrine pathway produce significant weight loss in pediatric patients compared to lifestyle-only interventions?
Key Response
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It promotes weight loss by delaying gastric emptying and acting directly on the hypothalamus to increase satiety and decrease hunger. Understanding this incretin effect helps students connect basic gastrointestinal endocrinology to the clinical outcomes observed in modern obesity management.
Given the significant BMI reduction seen in this trial, what are the most common adverse effects you must counsel parents about when initiating semaglutide in a young child, and how would you manage them clinically?
Key Response
The most frequent adverse effects are gastrointestinal, including nausea, vomiting, diarrhea, and constipation. Residents need to know how to dose-titrate slowly and counsel families on eating smaller, more frequent meals to mitigate these side effects and prevent early discontinuation of the medication.
In prepubertal children aged 6 to 11 with severe obesity, how might the profound weight loss achieved with semaglutide impact longitudinal growth velocity, bone mineral accretion, and pubertal timing, and what specific monitoring protocols should be implemented?
Key Response
Rapid weight loss in prepubertal children can theoretically alter linear growth, bone density, and the physiological onset of puberty. Fellows in pediatric endocrinology must consider these subspecialty-level impacts and design long-term monitoring strategies, such as tracking bone age and pubertal staging, rather than just monitoring BMI.
How should we navigate the ethical and practical dilemmas of starting a potentially lifelong, expensive subcutaneous medication in a 6-year-old child, particularly considering the rebound weight gain observed in adult trials upon drug cessation?
Key Response
Attendings must balance the immediate, profound metabolic benefits with long-term realities. This involves complex shared decision-making with families regarding cost, injection fatigue, adherence, and the reality that obesity is a chronic disease likely requiring indefinite therapy to maintain the 13.5% BMI reduction.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
How might the use of BMI percentage reduction as the primary endpoint limit our understanding of semaglutide's true effect on body composition in growing prepubertal children, and what alternative imaging or biomarker endpoints should future trials incorporate?
Key Response
BMI is an imperfect proxy for adiposity in growing children. A researcher would critique the potential lack of dual-energy X-ray absorptiometry (DXA) or advanced metabolic phenotyping to differentiate fat mass loss from critical lean muscle and bone mass alterations during this crucial developmental window.
To what extent does the unblinding risk due to distinct gastrointestinal side effects in the semaglutide arm threaten the internal validity of the efficacy outcomes, and how adequately did the authors address missing data through their chosen estimand framework?
Key Response
GI side effects often functionally unblind GLP-1 trials. An editor would heavily scrutinize how the trial handled treatment-policy estimands and missing data (e.g., using jump-to-reference imputation) to ensure the reported BMI reduction wasn't artificially inflated by missingness or placebo arm dropout.
The 2023 AAP guidelines on childhood obesity strongly recommend pharmacotherapy for children aged 12 and older; based on this 68-week Phase 3 data, should the age threshold for initiating GLP-1 agonists be formally lowered to 6 years, and what evidence grade would support this update?
Key Response
Current AAP guidelines support adjunct pharmacotherapy starting at age 12. This randomized, placebo-controlled trial provides high-quality (Level A) evidence that could justify lowering the treatment threshold to age 6 for severe pediatric obesity, forcing a major paradigm shift in pediatric obesity clinical practice guidelines.
Clinical Landscape
Noteworthy Related Trials
SCALE Teens Trial
Tested
Liraglutide 3.0 mg daily
Population
Adolescents (12-18 years) with obesity
Comparator
Placebo
Endpoint
Change in BMI standard-deviation score at week 56
STEP TEENS Trial
Tested
Semaglutide 2.4 mg once weekly
Population
Adolescents (12-18 years) with obesity
Comparator
Placebo
Endpoint
Percentage change in BMI from baseline to week 68
SCALE Kids Trial
Tested
Liraglutide 3.0 mg daily
Population
Children 6 to <12 years of age with obesity
Comparator
Placebo
Endpoint
Percentage change in BMI at week 56
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis